Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chlorprothixene→

Chlorprothixene Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
113-59-7
Molecular formula
C18H18ClNS
Molecular weight
315.86 g/mol
Drug class
Thioxanthene antipsychoticdopamine D2 receptor antagonist
Mechanism of action
Antagonises dopamine D2 receptors in central dopaminergic pathways, reducing psychotic symptoms. It also has histamine H1, alpha-adrenergic and muscarinic receptor antagonism that contributes to sedative and autonomic effects.
Indications / reported uses
  • Treatment of schizophrenia and other psychotic disorders in countries where chlorprothixene remains authorised; use and availability are jurisdiction-specific

Sources: NLM MeSH — Chlorprothixene · PubMed — Chlorprothixene antipsychotic pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chlorprothixene Environmental Risk Assessment (ERA) (the Chlorprothixene ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.